Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) announced results from a Phase 2 trial showing its investigational ZORYVE cream improved atopic dermatitis ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA